Oxaprozin

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
Oct 29, 1992	DayproNDA 18841 · New molecular entity	Pfizer	25	Discontinued
Jan 31, 2001	OxaprozinANDA 75845	Pangea	10	Marketed
Jan 31, 2001	OxaprozinANDA 75855	Dr Reddys Labs Ltd	6	Marketed
Feb 9, 2001	OxaprozinANDA 75848	Watson Labs	4	Discontinued
Feb 28, 2001	OxaprozinANDA 75847	Mylan Pharms Inc	1	Discontinued
Apr 12, 2001	OxaprozinANDA 75842	Aarxion Anda Hlding	0	Discontinued
Apr 27, 2001	OxaprozinANDA 75850	Sandoz	2	Discontinued
Aug 17, 2001	OxaprozinANDA 75851	Pharmobedient	2	Discontinued
Oct 3, 2001	OxaprozinANDA 75843	Actavis Elizabeth	2	Discontinued
Jan 3, 2002	OxaprozinANDA 75844	Sun Pharm Inds Inc	6	Discontinued
May 13, 2002	OxaprozinANDA 75846	Ivax Sub Teva Pharms	0	Discontinued
Jul 3, 2002	OxaprozinANDA 75849	Teva	10	Discontinued
Sep 2, 2004	OxaprozinANDA 75987	Chartwell	4	Marketed
May 4, 2017	OxaprozinANDA 208633	Amneal Pharms Co	3	Marketed
Oct 20, 2023	CoxantoNDA 217927 · New dosage form	Solubiomix	1	Marketed

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA